|Bid||1.03 x 1000|
|Ask||1.24 x 1800|
|Day's Range||1.05 - 1.08|
|52 Week Range||1.02 - 6.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 17, 2017 - Mar 20, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.35|
Amedica Corporation (NASDAQ:AMDA) is a small-cap stock with a market capitalization of US$4.80M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...
On Wednesday, May 23, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. This Thursday morning, WallStEquities.com looks at the performance of these four Medical Appliances & Equipment stocks: Abbott Laboratories (NYSE: ABT), ABIOMED Inc. (NASDAQ: ABMD), Align Technology Inc. (NASDAQ: ALGN), and Amedica Corp. (NASDAQ: AMDA).
Amedica Corporation (AMDA) an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications, today announced the closing of its previously announced public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Amedica. The offering was comprised of units, priced at a public offering price of $1,000 per unit. Each unit consists of one share of Series B Convertible Preferred Stock, with a stated value of $1,100, and 758 common stock purchase warrants (the “Warrants”).
Amedica Corporation (AMDA) an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications, today announced the pricing of an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Amedica. The offering will be priced at a public offering price of $1,000 per unit. Each unit consists of one share of Series B Convertible Preferred Stock, with a stated value of $1,100, and warrants to purchase up to 758 shares of common stock (the “Warrants”).
NEW YORK, NY / ACCESSWIRE / May 9, 2018 / Aralez Pharmaceutical shares sunk on Tuesday after reporting first quarter results, despite a third consecutive quarter of positive adjusted EBITDA. Shares of Amedica had a better day yesterday exploding to a close of over 180% after providing Wall Street with some updates on its clinical study activities. The innovative biomaterial company saw its shares explode after providing an update on its clinical study activities including a Single Center Retrospective Comparative Study and a Multi-Center Retrospective Study.
Amedica Corporation (AMDA), an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications, today provided an update on its clinical study activities. A clinical study comparing silicon nitride spinal implants to allograft spacers in cervical fusion showed faster and more effective outcomes with silicon nitride. “While silicon nitride might have been expected to perform better in light of its properties, the surprising finding in our study was how good the outcomes with silicon nitride proved to be. Significantly earlier and more effective bone fusion was observed with silicon nitride than allograft spacers at 3- 6-, and 12-month time points after surgery, all the way to 24 months” said Dr. Micah Smith, orthopaedic surgeon in Fort Wayne, Indiana, who is the principal investigator. Study findings have been submitted to for release at the December 2018 Cervical Spine Research Society meeting.
The latest earnings release Amedica Corporation’s (NASDAQ:AMDA) announced in December 2017 confirmed company earnings became less negative compared to the previous year’s level – great news for investors Below, I’veRead More...
SALT LAKE CITY, March 30, 2018-- Amedica Corporation, an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, is pleased to announce ...
Assessing Amedica Corporation’s (NASDAQ:AMDA) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met or exceedRead More...
Categories: Yahoo FinanceGet free summary analysis Amedica Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Amedica Corp. – Alphatec Holdings, Inc., Medtronic plc, CONMED Corporation, Stryker Corporation, Exactech, Inc., Zimmer Biomet Holdings, Inc., Johnson & Johnson, Kyocera Corporation Sponsored ADR and Globus Medical, Inc. ... Read more (Read more...)
Stock Monitor: Amedica Post Earnings Reporting LONDON, UK / ACCESSWIRE / November 28, 2017 / Active-Investors issued a free report on Hologic, Inc. (NASDAQ: HOLX ), which is readily accessible upon registration ...
In this article, I’m going to take a look at Amedica Corporation’s (NASDAQ:AMDA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
NEW YORK, NY / ACCESSWIRE / November 21, 2017 / Amedica Corp. (NASDAQ: AMDA ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 21, 2017 at 11:00 AM Eastern Time. ...
While small-cap stocks, such as Amedica Corporation (NASDAQ:AMDA) with its market cap of USD $10.18M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...